# Generate Biomedicines and Zealand Pharma agree AI-designed obesity protein deal

Canonical page: https://technooptimist.io/stories/generate-biomedicines-and-zealand-pharma-agree-ai-designed-obesity-080efba2
Date: 13 Oct 2026
About: [Generate Biomedicines](https://technooptimist.io/companies/generate-biomedicines.md) · [GB-0895 (anti-TSLP)](https://technooptimist.io/biotech/gb-0895.md)
Original source: https://kfgo.com/2026/10/13/zealand-pharma-generate-strike-ai-obesity-drug-deal-worth-up-to-1-2-billion/

Generate Biomedicines and Zealand Pharma will develop multispecific protein therapies for obesity and other metabolic diseases, using Generate's AI platform. Generate leads research through candidate selection; Zealand takes over clinical development, regulatory submissions and worldwide commercialisation.

## Key facts

- Generate receives $30 million upfront and is eligible for up to $35 million in early preclinical milestones.
- Total milestone payments are described as nearly $1.2 billion.
- Multispecific therapies act on more than one biological target at once, so one medicine could address several obesity-linked pathways.
- No specific program or target is named in the announcement.

---

The Techno Optimist tracks every frontier of technology, program by program: https://technooptimist.io/ (a Markdown version of any page: add .md to its URL; site map for agents: https://technooptimist.io/llms.txt).
Data API (JSON, realtime stream): https://technooptimist.io/developers. People read 5 pages free, then Reader $10/month; these Markdown pages are open to agents.